Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT01843374
First received: April 22, 2013
Last updated: November 17, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)